Nasdaq Stockholm

IRLAB Therapeutics AB

ISIN SE0012675361Filings at the FI

At a glance

Most recent filing on July 9, 2026 — an open-market purchase by James Gamgort on Jul 8, 2026.

We hold 43 visible filings, going back to July 10, 2019.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 43 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 43. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

James Gamgort Board member
$1,470Open-market buy
TradedJul 8, 2026FiledJul 9, 2026
James Gamgort Board member
$30,000Open-market buy
TradedJul 7, 2026FiledJul 9, 2026
Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body
140,000 SEKOpen-market buy
TradedNov 20, 2025FiledNov 20, 2025
Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body
120,000 SEKOpen-market buy
TradedNov 12, 2025FiledNov 12, 2025
Kristina Torfgård Chief executive officer
70,875 SEKOpen-market buy
TradedAug 5, 2024FiledAug 5, 2024